Deargen logo

Deargen

AI-First Pharmatech Company. We are exploring sequence-based drug discovery and development.

11 employees · est. 2016 · Daejeon, Korea South

VS
Protai logo

Protai

Proteomics & AI Drug discovery

29 employees · est. 2021 · Israel

Deargen is the older company (2016 vs 2021).

Side-by-Side Comparison

Deargen Protai
Founded
2016 older 2021
Headquarters
Daejeon, Korea South Israel
Employees
11 29
Industry
AI, Biotechnology, Machine Learning AI, Biotechnology, Life Sciences
Funding Stage
Series B Seed
Total Funding
$23.00B $20.00M
Funding Rounds
3 2
Services
AI Platform for Drug Discovery, New Drug Development, Molecular Optimization, Target Affinity Prediction, Toxicity-Centered Drug Design Structural Proteomics Integration, AI-Driven Drug Discovery, Pipeline Development, End-to-End Drug Discovery Collaboration, AIMS™ Platform Utilization
Target Customers
Pharmaceutical Companies, Biotech Firms, Medical Research Institutions, Drug Development Organizations, AI-Driven Healthcare Providers Pharmaceutical Companies, Biotech Firms, Research Institutions, Healthcare Innovators, Partnering Enterprises
Taxonomy
AI-driven Drug Discovery, Sequence-based Drug Development, Transformer Technology In Pharmaceuticals, Hit/Lead Compound Discovery, End-to-end AI Solution, Biotechnology Innovation, Genome Analysis Service, Deep Learning In Pharma, Computational Chemistry, Medicinal Chemistry, Target Discovery, Lead Optimization, AI In Healthcare, Pharmatech Innovation, Drug Design And Development Proteomics, AI Drug Discovery, End-to-End AI Platform, Cellular Function Analysis, Biological Insights, Complex Disease Combat, Protein Level Mapping, Drug Candidate Creation, Drug Discovery Facilitation, Advanced Drug Discovery, Disease Mapping, Molecular Biology, Pharmaceutical Innovation, Biotech
Website
deargen.me protai.bio
Deargen logo

About Deargen

Deargen, founded in 2016, positions itself as a pioneer in the intersection of AI and pharmaceuticals. This AI-First Pharmatech Company focuses on revolutionizing drug discovery and development through sequence-based AI solutions. Headquartered in Korea South, the company leverages advanced AI, part...

Protai logo

About Protai

Protai, founded in 2021 and headquartered in Israel, leverages cutting-edge technologies in AI, Biotechnology, and Life Sciences to revolutionize drug discovery. By utilizing an AI-based platform, Protai delves into the proteomic landscape to map diseases at the protein level, offering a novel appro...

We will tell you when either one moves

BounceWatch watches Deargen and Protai for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Deargen and Protai — by email.

Frequently Asked Questions

Deargen — AI-First Pharmatech Company. We are exploring sequence-based drug discovery and development. . Protai — Proteomics & AI Drug discovery . Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Deargen has raised $23.00B while Protai has raised $20.00M.
Deargen and Protai operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Deargen with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at Deargen on 15 Jun 2026, and Protai on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy